FIELD: medicine.
SUBSTANCE: group of inventions relates to immunology, and can be used for measuring cell-mediated immune response activity in a subject. Method comprises coincubation of a sample comprising lymphocytes from the subject, with at least two sets of peptides, derived from the protein antigen. First set being detected by CD8+ lymphocytes comprises at least one peptide of from 7 to 14 amino acid residues. Second set being detected by CD4+ lymphocytes comprises one peptide of 16 or more amino acid residues. Peptides cover the entire length of the protein antigen or a portion of the protein antigen. Presence or elevation in the level of an immune effector molecule from effector T-cells is measured. Presence or level of the immune effector molecule for T-cells is indicative of the level of cell-mediated responsiveness of the subject. Use and a method for determining the status of cell- mediated immuno responsiveness of a subject are also provided.
EFFECT: group of inventions allows to measure the general cell-mediated immune response from CD4+ and from CD8+ lymphocytes, by increasing the sensitivity and specificity of the measurement method.
24 cl, 9 tbl, 2 dwg, 5 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS FOR PREDICTION OF APPLICABILITY OF PROTEINS OR PROTEIN FRAGMENTS FOR IMMUNOTHERAPY | 2017 |
|
RU2782336C2 |
ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2018 |
|
RU2794945C2 |
ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2792042C2 |
METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
MODIFIED EPITOPES FOR AMPLIFYING RESPONSES OF CD4+ T-CELLS | 2013 |
|
RU2724994C2 |
PREDICTION OF IMMUNOGENICITY OF T-CELL EPITOPES | 2014 |
|
RU2724370C2 |
IMMUNOGENIC COMPOSITIONS OF MULTIPLE ANTIGEN PRESENTATION, METHODS AND APPLICATIONS RELATING THERETO | 2012 |
|
RU2619176C2 |
CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | 2014 |
|
RU2820869C1 |
Authors
Dates
2018-03-15—Published
2012-06-27—Filed